InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,018.39
(
-0.34%
)
US TECH 100
16,952.00
(
-0.19%
)
Dow Jones
37,903.29
(
0.23%
)
Brent Oil
83.82
(
0.33%
)
Bitcoin
57,497.15
(
-1.27%
)
Post# of 97237
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

beach_trades

Send PM Follow Ignore
Followers 425
Posts 20207
Boards Moderated 1
Alias Born 02/22/2010

beach_trades

Re: None

Monday, 09/26/2016 10:13:52 AM

Monday, September 26, 2016 10:13:52 AM

Post# of 97237
$GTXI swinging about .76 avg in Q4 catalyst

Enobosarm, a selective androgen receptor modulator (SARM), is the Company’s lead product candidate and is being developed as a targeted treatment for two advanced breast cancer indications: estrogen receptor positive (ER+) and androgen receptor positive (AR+) breast cancer, and AR+ triple negative breast cancer (TNBC). Preliminary data from the first stage of both Phase 2 clinical trials are expected by the end of 2016

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up